Yantai Dongcheng Beifang Pharmaceutical Co. Ltd.

1. To study the pharmacodynamics of domestic nadroparin calcium for injection and original nadroparin calcium injection in healthy Chinese male subjects after crossover, single, subcutaneous injection, and evaluate whether there is bioequivalence between the two preparations. 2. To study the pharmacokinetics of nadroparin calcium (anti-factor Xa activity PK, anti-factor IIa activity PK).

Main objective: To investigate the pharmacodynamic characteristics of a single subcutaneous injection of the test formulation, bemiparin sodium injection (0.2 mL: 3500 Xa IU, manufactured by Yantai Dongcheng Northern Pharmaceutical Co., Ltd.), and the reference formulation, bemiparin sodium injection (Xibao®, 0.2 mL: 3500 IU (anti-Xa); manufactured by ROVI PHARMA INDUSTRIAL SERVICES, S.A.), in healthy participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting subcutaneous injection. Secondary objective: To investigate the safety of the test formulation, bemiheparin sodium injection (specification: 0.2 mL: 3500 IU Xa), and the reference formulation, bemiheparin sodium injection (Xiabao®) (specification: 0.2 mL: 3500 IU (anti-Xa)), in healthy participants.